3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Leukemia, Myeloid, Acute
25
Advanced Solid Tumors
18
Breast Neoplasms
12
Myelodysplastic Syndromes
11
Neoplasms
10
Advanced Solid Tumor
10
Prostatic Neoplasms
9
Solid Tumor
7
Neoplasm Metastasis
7
Multiple Myeloma
7
Recurrence
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Melanoma
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia
4
Solid Tumors
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Primary Myelofibrosis
2
Nasopharyngeal Carcinoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Interventions
pembrolizumab
2
efineptakin alfa
1
MK 2206
1
Injections
1
Cetuximab
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Locally Advanced or Metastatic Solid Tumors
×
Injections
×
Clear all
NCT05957471
2023-07-24
BC3195
Biocity Biopharmaceutics Co., Ltd.
Phase 1
Unknown
27 enrolled